S&P 500   5,117.99 (+0.43%)
DOW   39,026.39 (+0.08%)
QQQ   443.40 (+1.00%)
AAPL   177.95 (-1.55%)
MSFT   412.95 (-0.17%)
META   499.42 (+1.90%)
GOOGL   137.73 (-0.53%)
AMZN   178.00 (+0.70%)
TSLA   200.85 (-0.51%)
NVDA   819.42 (+3.58%)
NIO   5.83 (+1.39%)
AMD   200.00 (+3.88%)
BABA   74.98 (+1.28%)
T   16.94 (+0.06%)
F   12.49 (+0.40%)
MU   95.41 (+5.30%)
CGC   3.27 (-0.61%)
GE   158.85 (+1.25%)
DIS   111.55 (-0.03%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.41 (+0.12%)
XOM   106.31 (+1.71%)
S&P 500   5,117.99 (+0.43%)
DOW   39,026.39 (+0.08%)
QQQ   443.40 (+1.00%)
AAPL   177.95 (-1.55%)
MSFT   412.95 (-0.17%)
META   499.42 (+1.90%)
GOOGL   137.73 (-0.53%)
AMZN   178.00 (+0.70%)
TSLA   200.85 (-0.51%)
NVDA   819.42 (+3.58%)
NIO   5.83 (+1.39%)
AMD   200.00 (+3.88%)
BABA   74.98 (+1.28%)
T   16.94 (+0.06%)
F   12.49 (+0.40%)
MU   95.41 (+5.30%)
CGC   3.27 (-0.61%)
GE   158.85 (+1.25%)
DIS   111.55 (-0.03%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.41 (+0.12%)
XOM   106.31 (+1.71%)
S&P 500   5,117.99 (+0.43%)
DOW   39,026.39 (+0.08%)
QQQ   443.40 (+1.00%)
AAPL   177.95 (-1.55%)
MSFT   412.95 (-0.17%)
META   499.42 (+1.90%)
GOOGL   137.73 (-0.53%)
AMZN   178.00 (+0.70%)
TSLA   200.85 (-0.51%)
NVDA   819.42 (+3.58%)
NIO   5.83 (+1.39%)
AMD   200.00 (+3.88%)
BABA   74.98 (+1.28%)
T   16.94 (+0.06%)
F   12.49 (+0.40%)
MU   95.41 (+5.30%)
CGC   3.27 (-0.61%)
GE   158.85 (+1.25%)
DIS   111.55 (-0.03%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.41 (+0.12%)
XOM   106.31 (+1.71%)
S&P 500   5,117.99 (+0.43%)
DOW   39,026.39 (+0.08%)
QQQ   443.40 (+1.00%)
AAPL   177.95 (-1.55%)
MSFT   412.95 (-0.17%)
META   499.42 (+1.90%)
GOOGL   137.73 (-0.53%)
AMZN   178.00 (+0.70%)
TSLA   200.85 (-0.51%)
NVDA   819.42 (+3.58%)
NIO   5.83 (+1.39%)
AMD   200.00 (+3.88%)
BABA   74.98 (+1.28%)
T   16.94 (+0.06%)
F   12.49 (+0.40%)
MU   95.41 (+5.30%)
CGC   3.27 (-0.61%)
GE   158.85 (+1.25%)
DIS   111.55 (-0.03%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.41 (+0.12%)
XOM   106.31 (+1.71%)
NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

$0.08
+0.00 (+2.50%)
(As of 10:55 AM ET)
Today's Range
$0.08
$0.08
50-Day Range
$0.07
$0.20
52-Week Range
$0.06
$1.31
Volume
642 shs
Average Volume
23,207 shs
Market Capitalization
$798,012.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BLCM stock logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Stock Price History

BLCM Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Bellicum Pharmaceuticals Inc BLCM
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Futura Medical plc (FAMDF)
BLCM - Bellicum Pharmaceuticals, Inc.
Short Volatility Alert: Bellicum Pharma
Why Bellicum Pharmaceuticals Stock Is Plunging Today
BLCM Bellicum Pharmaceuticals, Inc.
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
3/01/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-24,970,000.00
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.23 per share

Miscellaneous

Free Float
8,716,000
Market Cap
$778,572.00
Optionable
Not Optionable
Beta
1.39
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Charles S. Grass (Age 64)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 54)
    Senior Vice President of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $536.43k














BLCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View BLCM analyst ratings
or view top-rated stocks.

How have BLCM shares performed in 2024?

Bellicum Pharmaceuticals' stock was trading at $0.15 at the beginning of 2024. Since then, BLCM stock has decreased by 45.3% and is now trading at $0.0821.
View the best growth stocks for 2024 here
.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BLCM earnings forecast
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

When did Bellicum Pharmaceuticals' stock split?

Shares of Bellicum Pharmaceuticals reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLCM) was last updated on 3/1/2024 by MarketBeat.com Staff